Report of the 2023 Mary Tyler Moore Vision Initiative Workshop.

Area of Science:

• Ophthalmology
• Diabetology
• Biomedical Research

Background:

• Diabetic Retinal Disease (DRD) poses a significant threat to vision in individuals with diabetes.
• Current diagnostic and therapeutic strategies require advancement to preserve neurovascular integrity.
• The Mary Tyler Moore Vision Initiative (MTM Vision) aims to address these unmet needs.

Framework:

• The MTM Vision Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop convened over 130 experts.
• Participants included clinicians, scientists, industry representatives, and patient advocates.
• The workshop focused on developing new diagnostic and therapeutic approaches for DRD.

Implementation:

• Key MTM Vision projects include updating the DRD staging system and severity scale.
• Establishing a human ocular biorepository and resource is a priority.
• Validating clinical endpoints and biomarkers is crucial for accelerating drug development.

Implications:

• Accelerated development of novel drugs and therapies for diabetic retinopathy.
• Improved patient care and outcomes for individuals with diabetes.
• A public-private consortium is essential for achieving MTM Vision's objectives.